Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around.

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Cartesian Therapeutics reports sustained benefits of Descartes-08 CAR-T therapy in generalized myasthenia gravis patients, ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

Myasthenia gravis (MG) is a neuromuscular junction disorder clinically ... A 61-year-old male was first diagnosed with gMG in April 2023, when he presented with left-sided ptosis. The patient’s ...

According to Immunovant, the medicine, batoclimab, succeeded in a Phase 3 study of patients with myasthenia gravis and the first part of a Phase 2b trial focused on an immune condition that damages ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three ...